Search for content, post, videos

Betagenon receives EUR 1.8 million


The Umeå based company Betagenon receives €1,8 million, from EU’s sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and associated cardiovascular disease.

“An increase in calorie intake combined with an inactive life style has brought about a global epidemic of obesity, fatty liver and type 2 diabetes, all contributing to an increased risk of cardiovascular disease. There is an enormous need for effective treatments of these wide spread metabolic diseases. So this large financial support from EU is both very important and encouraging,” says Thomas Edlund, CEO of Betagenon and professor at Umeå University.

AMPK, AMP Activated Protein Kinase, is the master regulator of energy balance at single cell and whole organism level. Since its activity decreases with increasing age, obesity and inactivity, AMPK is a promising target to prevent/cure obesity, fatty liver, type 2 diabetes and cardiovascular disease associated with energy imbalance. Energy shortage activates AMPK that in turn restores energy balance by increasing glucose and lipid metabolism, suppressing anabolic processes, and at the same time increasing blood flow and thus delivery of nutrients to target tissues. Betagenons approach is to activate AMPK.
Betagenon’s substance O304 is the first AMPK activator to reach a clinical phase II trial to assess its efficacy and safety for patients with type 2 diabetes. In animal models the substance has already been shown to protect against diet induced obesity, fatty liver, insulin resistance, β-cell dysfunction, glucose intolerance, hyperlipidemia and diabetes. O304 also increases left ventricle stroke volume, cardiac output, peripheral blood flow and endurance (“Exercise mimetic”).

Betagenon’s EU application received an outstanding score 14.64 out of 15 in the EU evaluation, and the implementation section was regarded as perfect.